Regeneron Pharmaceuticals, Inc. operates as a fully integrated biotechnology company with a science-driven approach to drug discovery and development. The company's commercial portfolio includes blockbuster biologic drugs such as Eylea for macular degeneration and Dupixent for atopic dermatitis and asthma, which are often co-developed and commercialized through strategic partnerships with companies like Sanofi and Bayer. Regeneron leverages its proprietary VelociSuite platforms, including VelocImmune, to accelerate the traditional drug development process by generating fully human antibodies. Additionally, the Regeneron Genetics Center conducts large-scale genomic sequencing to identify new drug targets and validate existing ones. The company's clinical pipeline spans multiple therapeutic areas, including oncology, immunology, ophthalmology, and rare diseases.
